Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
02/01/19Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test
Agreement Enhances Commercial Presence in Organ Transplant Centers SAN CARLOS, Calif., Feb. 1, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced a partnership with Thermo Fisher Scientific's One Lambda brand, a global leader in human leukocyte antigen (HLA) typing and antibody monitoring assays for transplantation, to co-distribute Natera's kidney transplant rejection test in the United States in col... 
01/07/19Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection
Represents Successful Achievement of All 2018 Commercialization Milestones, on Path to 2019 Launch SAN CARLOS, Calif., Jan. 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced clinical validation study results published in the Journal of Clinical Medicine,1 demonstrating the highly accurate performance of its donor-derived cell-free DNA (dd-cfDNA) test for active allograft rejection in kidney transplant recipients, including higher sensitivity and... 
01/04/19Natera To Webcast Live Presentation at the 37th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif., Jan. 4, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced that it will webcast a live presentation at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, Jan. 9, 2019, at 1:30 p.m. Pacific Time. Natera's newly appointed CEO Steve Chapman and Executive Chairman Matthew Rabinowitz will provide... 
01/04/19Natera Obtains Z-Codes for Signatera MRD and Treatment Monitoring Test in Oncology
Represents Key Reimbursement Milestone In Line with Planned Clinical Launch SAN CARLOS, Calif., Jan. 4, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in non-invasive genetic testing and cell-free DNA, today announced the assignment of two Z-codes for the company's Signatera™ test, in preparation for its planned clinical launch in Q2 2019. Signatera, when clinically available, is intended for use by oncologists to detect molecular residual disease (MRD) and monitor treatm... 
01/02/19Natera Appoints Steve Chapman CEO and Robert Schueren COO; Matthew Rabinowitz Moves to Executive Chairman
Proven Commercial Execution Selected for CEO Role; Seasoned Operational Expertise Selected for COO Role SAN CARLOS, Calif., Jan. 2, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, has announced the appointment of Steve Chapman as Chief Executive Officer (CEO) effective today and Robert Schueren as Chief Operating Officer (COO) effective January 7, 2019. Previously, Chapman was the company's COO and will succeed Ma... 
Shareholder Tools